Litigation Details for ELI LILLY AND COMPANY v. GLENMARK GENERICS INC., USA (S.D. Ind. 2014)

ELI LILLY AND COMPANY v. GLENMARK GENERICS INC., USA (S.D. Ind. 2014)

Docket		Date Filed	2014-01-23
Court	District Court, S.D. Indiana	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Tanya Walton Pratt
Jury Demand	None	Referred To	Denise K. Larue
Patents	7,772,209
Link to Docket	External link to docket

Details for ELI LILLY AND COMPANY v. GLENMARK GENERICS INC., USA (S.D. Ind. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-01-23	1		prior to the expiration of U.S. Patent No. 7,772,209 (“the ’209 patent”). ALIMTA® is a chemotherapy agent… (Infringement of U.S. Patent No. 7,772,209) 13. Lilly incorporates… 1. This is an action for patent infringement under the patent laws of the United States, Title… assignee of the ’209 patent. As set forth in greater detail in the ’209 patent, one or more claims of…with respect to the ’209 patent, asserting that the claims of the ’209 patent are invalid, unenforceable	External link to document
2017-08-11	44		August 10, 2010, U.S. Patent No. 7,772,209 (“Patent ’209”) was issued to Lilly. Patent ’209 covers the method… Eli Lilly and Company’s United States Patent No. 7,772,209. Case No. 1:10-cv-1373-TWP-DKL, ECF 420…claims of [Patent ’209]; d. in the event that the asserted claims of [Patent ’209] patent are invalidated… to the Patent Trial and Appeal Board (“PTAB”) seeking inter partes review (“IPR”) of Patent ’209. Glenmark…the Court that Patent ’209 is invalid. Additionally, even if the PTAB ruled that Patent ’209 was invalid	External link to document